Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the European Commission (EC) granted marketing authorization in the European Union (EU) for a citrate-free high concentration formulation (HCF; 100 mg/mL) of its biosimilar Hyrimoz® (adalimumab). The approval…

Read MoreSandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

Labcorp and Jefferson Health Announce Strategic Laboratory Relationship

Physicians and Patients Will Gain Access to Enhanced Laboratory Services and Advanced Diagnostic Testing BURLINGTON, N.C., May 3, 2023 /PRNewswire/ — Labcorp (NYSE: LH), a leading global life sciences company, today announced an agreement to enter into a strategic relationship with Jefferson Health (Jefferson), the largest…

Read MoreLabcorp and Jefferson Health Announce Strategic Laboratory Relationship

Labcorp expands access to colorectal cancer screening through partnership with the Conference of National Black Churches

 Labcorp (NYSE: LH), a leading global life sciences company, is partnering with the Conference of National Black Churches (CNBC) to address health equity gaps in colorectal cancer screening. To raise awareness and provide expanded access to colorectal cancer screening tests, the Conference of National…

Read MoreLabcorp expands access to colorectal cancer screening through partnership with the Conference of National Black Churches

Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC), by a vote of 11 to 1 with one abstention, supported FDA…

Read MoreUpdate on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer